Literature DB >> 14693162

The effects of surgery, with or without rhGM-CSF, on the angiogenic profile of patients treated for colorectal carcinoma.

Francis P K Wu1, Johan R Westphal, Klaas Hoekman, Anneke K Mels, Markwin G Statius Muller, Robert W de Waal, Rob H J Beelen, Paul A M van Leeuwen, Sybren Meijer, Miguel A Cuesta.   

Abstract

Wound healing is a process with immunological and angiogenic aspects. rhGM-CSF is known to stimulate the immune system and angiogenesis via multiple pathways. In this study we investigated the combined effects of surgery, with or without rhGM-CSF, on angiogenic parameters in patients with a colorectal carcinoma. In this phase II randomized, placebo-controlled trial, 16 patients were assigned to perioperative rhGM-CSF (2.8 microg/kg body weight) treatment or saline. Patients received subcutaneous injections from three days before surgery until four days after. IL-6, VEGF, endostatin and angiostatin levels were measured perioperatively. rhGM-CSF enhanced the production of IL-6 and VEGF, but had no effect on the antiangiogenic agents endostatin and angiostatin. Surgery induced a transient decrease of endostatin. Two types of angiostatin (kringle 1-3 and kringle 1-4) became visible postoperatively. We conclude that this study demonstrated the immediate initiation of angiogenesis postoperatively, reflected by the increase of VEGF and a transient decrease of endostatin, followed by the appearance of two angiostatin bands, which confirms physiological wound healing in these cancer patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14693162     DOI: 10.1016/j.cyto.2003.09.010

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  8 in total

1.  Plasma soluble vascular adhesion molecule-1 levels are persistently elevated during the first month after colorectal cancer resection.

Authors:  H M C Shantha Kumara; Samer T Tohme; Sonali A C Herath; Xiaohong Yan; Anthony J Senagore; Abu Nasar; Matthew F Kalady; Raymond Baxter; Richard L Whelan
Journal:  Surg Endosc       Date:  2012-01-05       Impact factor: 4.584

2.  Major abdominal surgery increases plasma levels of vascular endothelial growth factor: open more so than minimally invasive methods.

Authors:  Avraham Belizon; Emre Balik; Daniel L Feingold; Marc Bessler; Tracey D Arnell; Kenneth A Forde; Patrick K Horst; Suvinit Jain; Vesna Cekic; Irena Kirman; Richard L Whelan
Journal:  Ann Surg       Date:  2006-11       Impact factor: 12.969

3.  Persistent elevation of plasma vascular endothelial growth factor levels during the first month after minimally invasive colorectal resection.

Authors:  A Belizon; E Balik; P Horst; D Feingold; T Arnell; T Azarani; V Cekic; R Skitt; S Kumara; R L Whelan
Journal:  Surg Endosc       Date:  2008-01-18       Impact factor: 4.584

4.  Minimally invasive colon resection for malignant colonic conditions is associated with a transient early increase in plasma sVEGFR1 and a decrease in sVEGFR2 levels after surgery.

Authors:  H M C Shantha Kumara; J C Cabot; A Hoffman; M Luchtefeld; M F Kalady; N Hyman; D Feingold; R Baxter; R L Whelan
Journal:  Surg Endosc       Date:  2009-06-24       Impact factor: 4.584

5.  Serum endostatin levels are elevated in colorectal cancer and correlate with invasion and systemic inflammatory markers.

Authors:  T Kantola; J P Väyrynen; K Klintrup; J Mäkelä; S M Karppinen; T Pihlajaniemi; H Autio-Harmainen; T J Karttunen; M J Mäkinen; A Tuomisto
Journal:  Br J Cancer       Date:  2014-08-19       Impact factor: 7.640

6.  GM-CSF enhances tumor invasion by elevated MMP-2, -9, and -26 expression.

Authors:  Claudia M Gutschalk; Archana K Yanamandra; Nina Linde; Alice Meides; Sofia Depner; Margareta M Mueller
Journal:  Cancer Med       Date:  2012-11-26       Impact factor: 4.452

Review 7.  Effects of surgery and anesthetic choice on immunosuppression and cancer recurrence.

Authors:  Ryungsa Kim
Journal:  J Transl Med       Date:  2018-01-18       Impact factor: 5.531

Review 8.  On the origin of myeloid-derived suppressor cells.

Authors:  Camilla Rydberg Millrud; Caroline Bergenfelz; Karin Leandersson
Journal:  Oncotarget       Date:  2017-01-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.